Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs

Pharvaris (NASDAQ:PHVS) – Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for shares of Pharvaris in a research note issued to investors on Tuesday, May 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($0.87) for the quarter, up from their previous estimate of ($0.91). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($3.58) EPS and FY2026 earnings at ($3.26) EPS.

Several other equities analysts also recently issued reports on the company. JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, January 31st. Cantor Fitzgerald cut their price objective on Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday.

Pharvaris Price Performance

Shares of PHVS stock opened at $16.56 on Friday. The stock’s fifty day simple moving average is $15.38 and its 200 day simple moving average is $17.68. The firm has a market cap of $865.92 million, a price-to-earnings ratio of -5.91 and a beta of -2.85. Pharvaris has a one year low of $11.51 and a one year high of $25.50.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after acquiring an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Pharvaris during the fourth quarter worth about $64,000. Barclays PLC bought a new stake in Pharvaris during the third quarter worth about $106,000. KLP Kapitalforvaltning AS bought a new stake in Pharvaris during the fourth quarter worth about $111,000. Finally, Point72 Asset Management L.P. bought a new stake in Pharvaris during the fourth quarter worth about $152,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.